JAKAVI (Novartis Pharmaceuticals Australia Pty Ltd)
Product name
JAKAVI
Date registered
Evaluation commenced
Decision date
Approval time
142 (175 working days)
Active ingredients
Ruxolitinib phosphate
Registration type
EOI
Indication
- Jakavi is indicated for the treatment of patients aged 28 days and older with acute graft-versus-host disease who have inadequate response to corticosteroids.
- Jakavi is indicated for the treatment of patients aged 6 months and older with chronic graft-versus-host disease who have inadequate response to corticosteroids